Norges Bank Edgewise Therapeutics, Inc. Transaction History

Norges Bank

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2023	BUY	$9.1 - $18.97 $2.75 Million - $5.72 Million	301,691 New	301,691 $2.93 Million
Q1 2022 May 09, 2022	SELL	$9.1 - $18.97 $2.75 Million - $5.72 Million	-301,691 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$14.41 - $22.41 $4.35 Million - $6.76 Million	301,691 New	301,691 $4.61 Million
Q3 2021 Nov 14, 2022	BUY	$14.11 - $24.1 $4.26 Million - $7.27 Million	301,691 New	301,691 $5.01 Million
Q3 2021 Nov 05, 2021	SELL	$14.11 - $24.1 $4.26 Million - $7.27 Million	-301,691 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$21.33 - $30.25 $6.44 Million - $9.13 Million	301,691 New	301,691 $6.44 Million
Q2 2021 Aug 10, 2021	SELL	$21.33 - $30.25 $9.58 Million - $13.6 Million	-449,000 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$30.0 - $35.99 $13.5 Million - $16.2 Million	449,000 New	449,000 $14.6 Million

191

100M

2.17M

410K

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $1.94B
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.